Last year, the National Institute of Health and Care Excellence (NICE) published guidance that brentuximab should be available on the NHS for people with Hodgkin lymphoma who had already had an autologous stem cell transplant but needed more treatment.
At the time, there was limited evidence that brentuximab could help people who had received at least two previous courses of treatment but could not have a stem cell transplant or chemotherapy with a combination of different drugs. Brentuximab was therefore made available through the Cancer Drugs Fund for this use while more evidence was gathered.
We are pleased to report that new evidence was recently reviewed and brentuximab will now be made available on the NHS for this use.
Find out more in the NICE guidance published on 13 June 2018.